当前位置： SCI文献检索 > Cancer Discovery期刊下所有文献 > ARID1A mutations in cancer: another epigenetic tumor suppressor?

ARID1A mutations in cancer: another epigenetic tumor suppressor?

Abstract：

UNLABELLED:Although disordered chromatin organization has long been recognized as a feature of cancer, the molecular underpinnings of chromatin structure, epigenetic regulation, and their relationships to transcription are only beginning to be understood. Cancer genome sequencing studies have revealed a novel theme: frequent mutation of epigenetic regulators. Among these, the ARID1A/BAF250A subunit of the SWI/SNF (BRG1-associated factors) chromatin remodeling complex has emerged as recurrently mutated in a broad array of tumor types. We review the genomic and functional data supporting classification of ARID1A as a tumor suppressor. SIGNIFICANCE:Mutations in chromatin remodeling complex genes are increasingly recognized in many cancer types. However, the mechanisms by which chromatin remodeling complexes contribute to gene expression and the cancer phenotype are poorly understood. Understanding how mutation of chromatin remodelers facilitates transformation may offer the potential for development and implementation of novel therapies for cancer.

journal_name

Cancer Discov

journal_title

Cancer discovery

authors

Wu JN,Roberts CW

doi

10.1158/2159-8290.CD-12-0361

subject

Has Abstract

pub_date

2013-01-01 00:00:00

pages

35-43

issue

1

eissn

2159-8274

issn

2159-8290

pii

2159-8290.CD-12-0361

journal_volume

3

pub_type

杂志文章,评审

相关文献

Cancer Discovery文献大全
  • E-cigarettes Best Other Cessation Tools.

    abstract：:Electronic cigarettes (e-cigarettes) may be an effective tool for smoking cessation. In a randomized trial, researchers found that 18% of those assigned to use e-cigarettes were smoke-free after a year, compared with 9.9% of those assigned to nicotine replacement therapies such as patches and gum. However, those in th...

    journal_title：Cancer discovery

    pub_type： 评论,新闻

    doi：10.1158/2159-8290.CD-NB2019-018

    authors：

    更新日期：2019-04-01 00:00:00

  • Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.

    abstract：:Effective targeted therapeutics for squamous cell carcinoma (SCC) are lacking. Here, we uncover Mcl-1 as a dominant and tissue-specific survival factor in SCC, providing a roadmap for a new therapeutic approach. Treatment with the histone deacetylase (HDAC) inhibitor vorinostat regulates Bcl-2 family member expression...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-12-0417

    authors： He L,Torres-Lockhart K,Forster N,Ramakrishnan S,Greninger P,Garnett MJ,McDermott U,Rothenberg SM,Benes CH,Ellisen LW

    更新日期：2013-03-01 00:00:00

  • Database Drives Biomarker Research.

    abstract：:The Genomics of Drug Sensitivity in Cancer project recently added 4 years of additional data to a large-scale database designed to identify predictive biomarkers for cancer therapies. Freely available online, these data are driving research on the relationship between genomic features and drug responses to better tail...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2019-114

    authors：

    更新日期：2019-11-01 00:00:00

  • Checkpoint Kinase MEC1 (ATR) Structure Reveals Activation Mechanism.

    abstract：:Mutating a conserved motif in the activation loop of MEC1 (ATR) revealed the activation mechanism. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-RW2020-170

    authors：

    更新日期：2020-11-20 00:00:00

  • Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.

    abstract：:Venetoclax-based therapy can induce responses in approximately 70% of older previously untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well as relapse following initial response demonstrates the need for a deeper understanding of resistance mechanisms. In the present study, we rep...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-19-0710

    authors： Pei S,Pollyea DA,Gustafson A,Stevens BM,Minhajuddin M,Fu R,Riemondy KA,Gillen AE,Sheridan RM,Kim J,Costello JC,Amaya ML,Inguva A,Winters A,Ye H,Krug A,Jones CL,Adane B,Khan N,Ponder J,Schowinsky J,Abbott D,Ham

    更新日期：2020-04-01 00:00:00

  • Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer.

    abstract：:Triple-negative breast cancer (TNBC) is an aggressive and highly lethal disease. Because of its heterogeneity and lack of hormone receptors or HER2 expression, targeted therapy is limited. Here, by performing a functional siRNA screening for 2-OG-dependent enzymes, we identified gamma-butyrobetaine hydroxylase 1 (BBOX...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-20-0288

    authors： Liao C,Zhang Y,Fan C,Herring LE,Liu J,Locasale JW,Takada M,Zhou J,Zurlo G,Hu L,Simon JM,Ptacek TS,Andrianov VG,Loza E,Peng Y,Yang H,Perou CM,Zhang Q

    更新日期：2020-11-01 00:00:00

  • First Trial of a DARPin for Cancer Shows Promising Efficacy Signal.

    abstract：:In a phase I trial, the DARPin MG0250 had an expected safety profile and early signs of efficacy. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-RW2021-001

    authors：

    更新日期：2021-01-08 00:00:00

  • Panel OKs CAR T Therapy for Leukemia.

    abstract：:An expert panel recommended approval of Novartis's experimental chimeric antigen T-cell therapy, tisagenlecleucel, for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. The therapy would be the first of its kind approved for cancer and has the potential to transform standard of...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2017-108

    authors：

    更新日期：2017-09-01 00:00:00

  • iRECIST Guideline Unveiled for Immunotherapies.

    abstract：:The new iRECIST guideline-developed in consultation with academics, drug companies, and regulatory authorities-provides a standardized approach to assessing whether patients' disease improves, stays the same, or worsens in trials of immunotherapeutics, agents that can trigger different response patterns from other kin...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-NB2017-037

    authors：

    更新日期：2017-05-01 00:00:00

  • Blood Monocyte Frequency May Be a Biomarker for Response to Anti-PD-1.

    abstract：:CD14+CD16-HLA-DRhi monocyte frequency was linked to response to anti-PD-1 in patients with melanoma. ...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-RW2018-016

    authors：

    更新日期：2018-03-01 00:00:00

  • Immunotherapy toxic in obese mice.

    abstract：:New research shows immunotherapy can cause lethal inflammation in both young and aged mice that are obese. Restricting calories in aged mice protected them from toxicity, and giving young obese mice a drug for autoimmune disease prevented the fatal reactions. ...

    journal_title：Cancer discovery

    pub_type： 新闻

    doi：10.1158/2159-8290.CD-NB2014-171

    authors：

    更新日期：2015-01-01 00:00:00

  • Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma.

    abstract：: Clear cell renal cell carcinoma (ccRCC) is characterized by loss of the von Hippel-Lindau tumor suppressor gene (VHL), and the functional tumorigenic consequences of this loss have been used to develop therapies for advanced ccRCC, such as targeting activation of the HIF pathway. Yao and colleagues elucidate how ...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-17-0971

    authors： Ricketts CJ,Linehan WM

    更新日期：2017-11-01 00:00:00

  • Not expecting the unexpected: diacylglycerol kinase alpha as a cancer target.

    abstract：:In this issue of Cancer Discovery, Dominguez and colleagues identify diacylglycerol kinase alpha (DGKα), an enzyme that converts the membrane lipid diacylglycerol to phosphatidic acid, as a central node upstream of mTOR and other oncogenic pathways. Importantly, targeting DGKα causes apoptosis in cancer cells and tumo...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-13-0244

    authors： Bhat KP,Aldape K

    更新日期：2013-07-01 00:00:00

  • Celgene Targets Blood Cancers with Major Buys.

    abstract：:Celgene acquired Juno Therapeutics for $9 billion and is spending up to $7 billion on Impact Biomedicines in an effort to diversify its hematology portfolio with chimeric antigen receptor T-cell therapies and a JAK2 inhibitor before its best seller, lenalidomide, faces competition from generics. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2018-007

    authors：

    更新日期：2018-03-01 00:00:00

  • Dual Checkpoint Blockade Takes Aim at Relapsed Mesothelioma.

    abstract：:In the largest clinical trial to date of immune checkpoint inhibitors for mesothelioma, patients treated with nivolumab-either alone or in combination with ipilimumab-posted impressive response rates and survival outcomes, according to data presented at the 2017 American Society of Clinical Oncology Annual Meeting. Ho...

    journal_title：Cancer discovery

    pub_type： 临床试验,杂志文章

    doi：10.1158/2159-8290.CD-NB2017-087

    authors：

    更新日期：2017-08-01 00:00:00

  • Innate αβ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming.

    abstract：:Unconventional T-lymphocyte populations are emerging as important regulators of tumor immunity. Despite this, the role of TCRαβ+CD4-CD8-NK1.1- innate αβ T cells (iαβT) in pancreatic ductal adenocarcinoma (PDA) has not been explored. We found that iαβTs represent ∼10% of T lymphocytes infiltrating PDA in mice and human...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-19-0161

    authors： Hundeyin M,Kurz E,Mishra A,Rossi JAK,Liudahl SM,Leis KR,Mehrotra H,Kim M,Torres LE,Ogunsakin A,Link J,Sears RC,Sivagnanam S,Goecks J,Islam KMS,Dolgalev I,Savadkar S,Wang W,Aykut B,Leinwand J,Diskin B,Adam S,Is

    更新日期：2019-09-01 00:00:00

  • Mutations in ERBB3 drive tumorigenesis.

    abstract：:Somatic ERBB3 hot-spot mutations promote oncogenic signaling in a subset of human tumors. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-RW2013-107

    authors：

    更新日期：2013-07-01 00:00:00

  • HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer.

    abstract：:Primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) drugs are clinically relevant problems in patients with metastatic colorectal carcinoma. A complex network of molecular alterations is involved in this phenomenon. Bertotti et al. report the development of serially transplantable groups of...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-11-0261

    authors： Ciardiello F,Normanno N

    更新日期：2011-11-01 00:00:00

  • Advancing the Precision Medicine Initiative.

    abstract：:The NIH has approved the framework to build a national research cohort of 1 million Americans, a key part of President Obama's Precision Medicine Initiative. ...

    journal_title：Cancer discovery

    pub_type： 新闻

    doi：10.1158/2159-8290.CD-NB2015-146

    authors：

    更新日期：2015-12-01 00:00:00

  • A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

    abstract：UNLABELLED:Despite the impressive clinical activity of the second-generation antiandrogens enzalutamide and ARN-509 in patients with prostate cancer, acquired resistance invariably emerges. To identify the molecular mechanisms underlying acquired resistance, we developed and characterized cell lines resistant to ARN-50...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-13-0226

    authors： Joseph JD,Lu N,Qian J,Sensintaffar J,Shao G,Brigham D,Moon M,Maneval EC,Chen I,Darimont B,Hager JH

    更新日期：2013-09-01 00:00:00

  • Pembrolizumab Approved for Hodgkin Lymphoma.

    abstract：:The FDA has approved pembrolizumab for adults and children with classical Hodgkin lymphoma whose disease is refractory to or has relapsed after at least three prior therapies. The approval marks the first time that a PD-1 inhibitor has been indicated for blood cancers-and for children. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2017-044

    authors：

    更新日期：2017-05-01 00:00:00

  • Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma.

    abstract：UNLABELLED:Adenoid cystic carcinoma (ACC), the second most common malignancy of salivary glands, is a rare tumor with a bleak prognosis for which therapeutic targets are unavailable. We used RNA sequencing (RNA-seq) to analyze low-quality RNA from archival, formaldehyde-fixed, paraffin-embedded samples. In addition to ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-15-0859

    authors： Brayer KJ,Frerich CA,Kang H,Ness SA

    更新日期：2016-02-01 00:00:00

  • Targeting HDAC And PI3K Inhibits MYC-Driven Medulloblastoma Growth.

    abstract：:HDAC inhibitors synergize with PI3K inhibitors to reduce MYC-driven medulloblastoma (MB) growth. ...

    journal_title：Cancer discovery

    pub_type： 评论,信件

    doi：10.1158/2159-8290.CD-RW2016-052

    authors：

    更新日期：2016-05-01 00:00:00

  • From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer.

    abstract：:DNA repair deficiencies are common among cancer cells and represent a potential vulnerability that might be exploited by targeting compensatory repair pathways. However, the identification of synthetically lethal combinations of DNA repair defects, although of significant clinical relevance, has been somewhat anecdota...

    journal_title：Cancer discovery

    pub_type：

    doi：10.1158/2159-8290.CD-14-0316

    authors： Hemann MT

    更新日期：2014-05-01 00:00:00

  • Improved survival ends nivolumab trial early.

    abstract：:A phase III trial testing nivolumab to treat advanced melanoma was stopped early due to improved overall survival compared with standard chemotherapy. ...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-NB2014-104

    authors：

    更新日期：2014-09-01 00:00:00

  • MET Promotes Antitumor Neutrophil Recruitment and Cytotoxicity.

    abstract：:MET is critical for antitumor neutrophil infiltration to HGF-secreting tumors and inflammatory sites. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-RW2015-097

    authors：

    更新日期：2015-07-01 00:00:00

  • CD10+GPR77+ Cancer-Associated Fibroblasts Promote Chemoresistance.

    abstract：:CD10 and GPR77 define a cancer-associated fibroblast (CAF) subset that sustains cancer stemness. ...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-RW2018-019

    authors：

    更新日期：2018-03-01 00:00:00

  • Sending CAR T Cells After Multiple Myeloma.

    abstract：:Preliminary results from an ongoing phase I clinical trial in China suggest that chimeric antigen receptor T cells engineered to home in on a protein called BCMA may be a potent therapeutic option for multiple myeloma. The therapy was well tolerated and induced complete, durable responses in patients with relapsed/ref...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2017-088

    authors：

    更新日期：2017-08-01 00:00:00

  • TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.

    abstract：UNLABELLED:Targeted molecular therapy has yielded remarkable outcomes in certain cancers, but specific therapeutic targets remain elusive for many others. As a result of two independent RNA interference (RNAi) screens, we identified pathway dependence on a member of the Janus-activated kinase (JAK) tyrosine kinase fami...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-12-0504

    authors： Sanda T,Tyner JW,Gutierrez A,Ngo VN,Glover J,Chang BH,Yost A,Ma W,Fleischman AG,Zhou W,Yang Y,Kleppe M,Ahn Y,Tatarek J,Kelliher MA,Neuberg DS,Levine RL,Moriggl R,Müller M,Gray NS,Jamieson CH,Weng AP,Staudt LM

    更新日期：2013-05-01 00:00:00

  • Neutrophils Provide Lipids to Metastatic Tumor Cells, Fueling Growth.

    abstract：:Lung mesenchymal cells promoted neutrophil lipid storage; lipids were transferred to tumor cells. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-RW2020-143

    authors：

    更新日期：2020-12-01 00:00:00